IBM Nanomedicine Discovery for Pancreatic Cancer
IBM scientists and their collaborators have discovered a potential efficient nanomedicine for treatment of fatal diseases such as pancreatic cancer.

Using the Blue Gene supercomputer, IBM researchers have shown for the first time that nanoparticle gadolinium metallofullerenol (Gd@C82(OH)22) binds to and blocks the enzyme responsible for tumor metastasis (the spread of the cancer), and survival.

Earlier this year, researchers discovered that metallofullerenol could bind to breast cancer but did not know how or where. IBM's work shows how gadolinium metallofullerenol acts as a nanomedicine by binding to cancer-instigating matrix metalloproteinase enzymes (MMPs).

MMPs degrade the extra-cellular matrix (ECM) that confine tumor tissues and spur blood vessel growth into the cancer cell. So, these enzymes not only help tumors grow and spread in the body, they keep them healthy.

Gadolinium metallofullerenol simulations inhibited pancreatic tumor growth by 50 percent. Similarly, breast cancer inhibition rate was between 40 and 50 percent.

The findings may aid in a new route of development of specific MMP inhibitors and effective anti-cancer nanomedicines.
3 photos · 1 video · 1,748 views